2026-10-21 12:36:48 UTC#493081duplicateconfirmedpress release
ENVB stock news
ENVB stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire12 wire items
2026-10-21 12:29:27 UTC#492970newconfirmedpress release
Enveric Biosciences (ENVB) reports positive results from IND-enabling ADMET studies
2026-09-15 12:12:53 UTC#313564newconfirmedpress release
Enveric Biosciences (ENVB) receives US patent allowance for EVM401 series non-hallucinogenic compounds
financial postimportance 0.40trust 0.80Enveric Biosciences, Inc. +0.40EVM401 +0.40Post-traumatic stress disorder +0.20
2026-08-18 16:25:42 UTC#190774duplicateconfirmednews
Enveric Biosciences acquires Cy Biopharma and secures $77M financing to extend cash runway to 2027
quartrimportance 0.30trust 0.60Enveric Biosciences, Inc. +0.50Cy Biopharma +0.40CY200 +0.50+1 entities
2026-08-18 15:50:37 UTC#190613newconfirmednews
Enveric Biosciences acquires PsyBio Pharma and secures $77M financing to advance CY200 CRPS trial
quartrimportance 0.50trust 0.70Enveric Biosciences, Inc. +0.40PsyBio Pharma Corp. +0.30CY200 +0.40+1 entities
2026-08-17 08:10:01 UTC#183471newconfirmeddata release
Enveric Biosciences Reports Q2 2026 GAAP EPS of -$0.76
2026-08-14 20:17:52 UTC#180081updateconfirmednews
Enveric Biosciences Q2 net loss widens, raises $6.5M and advances EB-003 IND-enabling studies
reutersimportance 0.40trust 0.80Enveric Biosciences, Inc. -0.30Joseph Tucker 0EB-003 +0.20+2 entities
2026-08-14 20:15:24 UTC#180180duplicateconfirmedpress release
Enveric Biosciences reports Q2 2026 financial results and EB-003 development progress
2026-08-14 20:05:00 UTC#180052updateconfirmedpress release
Enveric Biosciences reports Q2 2026 operational progress, including non-hallucinogenic profile data for EB-003
dow_jonesimportance 0.40trust 0.90Enveric Biosciences, Inc. +0.20EB-003 +0.30EVM401 +0.20+1 entities
2026-08-14 20:05:00 UTC#180051newconfirmeddata release
Enveric Biosciences (ENVB) reports Q2 2026 loss of $0.76 per share
2026-08-05 12:02:48 UTC#129701newconfirmedpress release
Enveric Biosciences reports new preclinical data supporting non-hallucinogenic profile of lead candidate EB-003
2026-07-28 12:08:41 UTC#87462newconfirmedpress release
Enveric Biosciences says new FDA guidance on psychedelic drug development supports EB-003 program
financial postimportance 0.40trust 0.90Enveric Biosciences, Inc. +0.40U.S. Food and Drug Administration +0.30EB-003 +0.40